leadf
logo-loader
viewKanabo Group PLC
(
LSE:KNB
)

Kanabo Group begins delivering breakthrough medicinal cannabis vape cartridges to UK

Kanabo Group PLC (LON:KNB) chief executive Avihu Tamir joins Proactive after passing a significant commercial 'milestone' with the shipment of its first medicinal cannabis cartridges to the UK. They will be sold by the LYPHE Group's clinics and dispensaries to be used with Kanabo’s VapePod device.

This is the first time a medicinal extract formula has been made available for inhalation by a metered-dose medical-grade vaporiser in the UK.

In North America, where the market is more developed than in Europe, vapes make up 20-30% of the market. UK doctors currently prescribe the drug for conditions such as severe epilepsy, multiple sclerosis and pain management.

Quick facts: Kanabo Group PLC

Follow
LSE:KNB

Price: 17.75 GBX

Market Cap: £65.51 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Kanabo Research sets sights on London listing

Israeli-based Kanabo Research could become the first cannabis firm to list on the main market of the London Stock Exchange. The company, which has developed a vaporiser for the inhalation of medical cannabis, is planning to list through a reverse takeover by cash shell Spinnaker...

on 1/7/19

2 min read